JP2025013884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025013884A5 JP2025013884A5 JP2024182581A JP2024182581A JP2025013884A5 JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5 JP 2024182581 A JP2024182581 A JP 2024182581A JP 2024182581 A JP2024182581 A JP 2024182581A JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- foxp3
- homology
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 125000006850 spacer group Chemical group 0.000 claims 7
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims 6
- 101150027879 FOXP3 gene Proteins 0.000 claims 5
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims 5
- 101710163270 Nuclease Proteins 0.000 claims 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108020005004 Guide RNA Proteins 0.000 claims 3
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims 3
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims 3
- 101150069263 tra gene Proteins 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 claims 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 claims 1
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 102000053917 human FOXP3 Human genes 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663545P | 2018-04-27 | 2018-04-27 | |
| US62/663,545 | 2018-04-27 | ||
| JP2020560400A JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| PCT/US2019/029082 WO2019210042A1 (en) | 2018-04-27 | 2019-04-25 | Expression of foxp3 in edited cd34+ cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Division JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025013884A JP2025013884A (ja) | 2025-01-28 |
| JP2025013884A5 true JP2025013884A5 (enExample) | 2025-04-10 |
Family
ID=68294731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
| JP2024182581A Pending JP2025013884A (ja) | 2018-04-27 | 2024-10-18 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560400A Active JP7575950B2 (ja) | 2018-04-27 | 2019-04-25 | 遺伝子編集されたｃｄ３４＋細胞におけるｆｏｘｐ３の発現 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11713459B2 (enExample) |
| EP (1) | EP3784690A4 (enExample) |
| JP (2) | JP7575950B2 (enExample) |
| CN (1) | CN112218882A (enExample) |
| AU (2) | AU2019261438B2 (enExample) |
| CA (1) | CA3091688A1 (enExample) |
| IL (1) | IL277039A (enExample) |
| SG (1) | SG11202007878UA (enExample) |
| WO (1) | WO2019210042A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016427822B2 (en) | 2016-10-31 | 2025-01-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene |
| CN112218882A (zh) * | 2018-04-27 | 2021-01-12 | 西雅图儿童医院（Dba西雅图儿童研究所） | Foxp3在经编辑的cd34+细胞中的表达 |
| US20210253652A1 (en) * | 2018-04-27 | 2021-08-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| EP3912644A4 (en) * | 2019-01-18 | 2022-09-28 | Osaka University | THERAPEUTIC AGENT FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA |
| CA3141159A1 (en) * | 2019-05-21 | 2020-11-26 | Sangamo Therapeutics, Inc. | Controlled transgene expression in regulatory t cells |
| NZ783217A (en) * | 2019-06-27 | 2025-08-29 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Artificial antigen-specific immunoregulatory t (airt) cells |
| EP4055039A1 (en) | 2019-11-08 | 2022-09-14 | Sangamo Therapeutics, Inc. | Generation of engineered regulatory t cells |
| WO2021144692A1 (en) * | 2020-01-14 | 2021-07-22 | Crispr Therapeutics Ag | Methods for increased efficiency of homology-directed repair |
| WO2021163642A2 (en) * | 2020-02-13 | 2021-08-19 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients |
| AU2021368557A1 (en) * | 2020-10-27 | 2023-06-08 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using next generation engineered t cell therapy |
| CN112851794B (zh) * | 2021-02-04 | 2023-05-23 | 苏州铂维生物科技有限公司 | 一种基于cd271的抗原表位及其应用 |
| GB202113674D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
| GB202113673D0 (en) | 2021-09-24 | 2021-11-10 | Reflection Therapeutics Ltd | Targeted cell therapies |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100996016B1 (ko) | 2000-09-20 | 2010-11-22 | 밀리포어 코포레이션 | 폴리뉴클레오티드 |
| JP4353701B2 (ja) | 2001-05-08 | 2009-10-28 | ダーウィン モレキュラー コーポレイション | Ｆｏｘｐ３蛋白質を用いた霊長類における免疫機能の調節方法 |
| GB0614536D0 (en) | 2006-07-21 | 2006-08-30 | Metcalfe Susan M | Methods of controlling cellular response to LIF |
| EP2064350B1 (en) * | 2006-11-27 | 2013-01-02 | Ludwig Institute for Cancer Research Ltd. | Expression of foxp3 by cancer cells |
| US20100135974A1 (en) | 2007-01-31 | 2010-06-03 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| US9249423B2 (en) | 2007-02-02 | 2016-02-02 | Yale University | Method of de-differentiating and re-differentiating somatic cells using RNA |
| US20110123502A1 (en) * | 2007-02-21 | 2011-05-26 | Barry Simon C | Method for obtaining treg-cells |
| WO2008141282A2 (en) | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
| WO2008154399A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Foxp3 oligomerization and intermolecular interactions |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| JP2011513403A (ja) | 2008-03-03 | 2011-04-28 | コンバージ バイオテック， インコーポレイテッド | Ｔ細胞依存性免疫応答を調節する方法 |
| WO2012018930A1 (en) | 2010-08-03 | 2012-02-09 | University Of Miami | Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy |
| WO2014180943A1 (en) | 2013-05-08 | 2014-11-13 | Vib Vzw | Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders |
| AU2014266833B2 (en) | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| DK3004337T3 (da) | 2013-05-29 | 2017-11-13 | Cellectis | Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system |
| JP6673838B2 (ja) | 2014-02-14 | 2020-04-01 | セレクティスＣｅｌｌｅｃｔｉｓ | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 |
| US20170198306A1 (en) | 2014-03-21 | 2017-07-13 | Cellectis | Engineering mammalian genome using dna-guided argonaute interference systems (dais) |
| KR101835554B1 (ko) | 2014-06-24 | 2018-04-19 | 서울대학교 산학협력단 | C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법 |
| EP3245294A4 (en) | 2015-01-12 | 2018-05-30 | Massachusetts Institute of Technology | Gene editing through microfluidic delivery |
| ES2880473T5 (es) * | 2015-01-30 | 2024-05-09 | Univ California | Suministro de proteínas en células hematopoyéticas primarias |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| US11499168B2 (en) | 2016-04-25 | 2022-11-15 | Universitat Basel | Allele editing and applications thereof |
| WO2018031762A1 (en) | 2016-08-10 | 2018-02-15 | Duke University | Compositions, systems and methods for programming immune cell function through targeted gene regulation |
| CA3034094A1 (en) * | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| WO2018073391A1 (en) * | 2016-10-19 | 2018-04-26 | Cellectis | Targeted gene insertion for improved immune cells therapy |
| WO2018081476A2 (en) | 2016-10-27 | 2018-05-03 | Intima Bioscience, Inc. | Viral methods of t cell therapy |
| AU2016427822B2 (en) | 2016-10-31 | 2025-01-23 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| CN109790518A (zh) | 2017-05-08 | 2019-05-21 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| EP3672617A4 (en) * | 2017-08-22 | 2021-06-23 | The Regents of the University of California | LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES |
| CN112218882A (zh) * | 2018-04-27 | 2021-01-12 | 西雅图儿童医院（Dba西雅图儿童研究所） | Foxp3在经编辑的cd34+细胞中的表达 |
| US20210253652A1 (en) | 2018-04-27 | 2021-08-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Expression of human foxp3 in gene edited t cells |
| WO2019241549A1 (en) | 2018-06-15 | 2019-12-19 | A2 Biotherapeutics, Inc. | Foxp3-expressing car-t regulatory cells |
-
2019
- 2019-04-25 CN CN201980028370.7A patent/CN112218882A/zh active Pending
- 2019-04-25 EP EP19793428.4A patent/EP3784690A4/en active Pending
- 2019-04-25 AU AU2019261438A patent/AU2019261438B2/en active Active
- 2019-04-25 JP JP2020560400A patent/JP7575950B2/ja active Active
- 2019-04-25 SG SG11202007878UA patent/SG11202007878UA/en unknown
- 2019-04-25 US US16/981,223 patent/US11713459B2/en active Active
- 2019-04-25 WO PCT/US2019/029082 patent/WO2019210042A1/en not_active Ceased
- 2019-04-25 CA CA3091688A patent/CA3091688A1/en active Pending
-
2020
- 2020-08-31 IL IL277039A patent/IL277039A/en unknown
-
2023
- 2023-06-16 US US18/336,276 patent/US20240117352A1/en active Pending
-
2024
- 2024-10-18 JP JP2024182581A patent/JP2025013884A/ja active Pending
- 2024-11-22 AU AU2024266824A patent/AU2024266824A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025013884A5 (enExample) | ||
| JP2025013879A5 (enExample) | ||
| JP2020518276A5 (enExample) | ||
| CN103224947B (zh) | 一种基因打靶系统 | |
| Ehrke-Schulz et al. | CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes | |
| He et al. | A simplified system for generating recombinant adenoviruses | |
| Di Matteo et al. | Recent developments in transposon-mediated gene therapy | |
| CN108546716A (zh) | 一种基因组编辑方法 | |
| JP2016165307A5 (enExample) | ||
| HK1223401A1 (zh) | 用於治疗遗传病状的方法和组合物 | |
| US20180163188A1 (en) | Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA | |
| JP2018516978A5 (enExample) | ||
| WO2016057961A1 (en) | Compositions and methods for promoting homology directed repair | |
| KR20160059994A (ko) | 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법 | |
| CN113195001B (zh) | 重组细小病毒载体及其制备方法和用途 | |
| JP2021502077A5 (enExample) | ||
| JPWO2020176740A5 (enExample) | ||
| JP2020511931A5 (enExample) | ||
| JP7765377B2 (ja) | Ｈｕｈエンドヌクレアーゼを用いた標的化ゲノム修飾を促進するための方法及び組成物 | |
| WO2024158864A1 (en) | Mb2cas12a variants with enhanced efficiency | |
| Lehmann et al. | Research on genodermatoses using novel genome‐editing tools | |
| JPWO2019210042A5 (enExample) | ||
| CN106282230B (zh) | 定点突变ldlr基因的方法 | |
| US20250019667A1 (en) | Adenoviral helper plasmid | |
| WO2001032899A1 (en) | Gene transfer method |